SEC EDGAROct 27$NXTC

ADAR1 Capital Management, LLC (Schneeberger Daniel) purchased $54K of NXTC (indirect holdings)

ADAR1 Capital Management, LLC purchased 10,851 indirectly-held shares of NextCure, Inc. (NXTC) at an average of $4.95 ($4.83–$5.10) across 3 trades over 2026-10-23 to 2026-10-27. Filed jointly with Schneeberger Daniel (10% owner).

Original reporting

SEC EDGAR · ADAR1 Capital Management, LLC, Schneeberger Daniel

Published Oct 27, 2026, 11:36 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Oct 27, 2026, 11:38 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$NXTC

Neutral

high confidence

Mentioned

$NXTC

Relevance

4/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$NXTCNeutralLow

Why it matters

The disclosed purchase is a primary source but its modest size limits market impact.

Market read

Insider purchase adds a small amount of buying pressure; unlikely to move the stock significantly.

What to watch

Potential upcoming clinical data or financing events not disclosed in this filing.

Relevance 4/10Novelty 4/10Timing: post-market filing on 2026-10-27

Background

SEC Form 4 filing reports an insider purchase by ADAR1 Capital Management, a 10% owner of NextCure.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NXTCNeutralHigh confidence

Context

Form 4 shows ADAR1 Capital Management bought 10,851 shares of NextCure at a weighted avg $4.95, total $53.7K, increasing its stake to 733,270 shares.

Expected impact

likely slight upward pressure as market prices in the insider buy

Evidence & confidence

The transaction is a primary filing but the dollar amount is trivial relative to market cap, limiting material impact.

Market effects

Sector

Minimal; biotech sector unlikely to move on a sub‑$100K insider purchase.

Regional

None; impact confined to NextCure shareholders.

Global

None

Counterpoint

What could challenge this read

The purchase could be a tactical move unrelated to fundamentals, offering no trading edge.

Key entities

company
NextCure, Inc.
Biotech firm listed on NASDAQ under ticker NXTC.
investor
ADAR1 Capital Management, LLC
Investment manager and 10% owner of NextCure.

Read at source ← All news

$NXTCHigh

NextCure, Inc. (NXTC): Reports Third Quarter 2026 Financial Results

NextCure, Inc. (NXTC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 NextCure Provides Business Update and Reports Third Quarter 2026 Financial Results – Advancing Toward Stockholder Approval of Proposed Merger with Avere Therapeutics Supported by Approximately $820 Million of Committed Financing – S-4 Declared Effective by SEC; S

SEC EDGAR 8-KNov 10

$LNTHMed

Weekly Buzz: LNTH, CBLL Win FDA Nod; AURA Cuts Jobs; TDY Buys VREX; CGEM, DFTX Meet Trial Goals

Biopharma roundup reported FDA/EC approvals and trial updates for Lantheus (LNTH) TAUKLARIFY, Ceribell (CBLL) AI EEG algorithms, Labcorp (LH) PGDx CDx, and EU/UK approvals for Galderma (GDERF) Restylane Shaype and Rhythm (RYTM) IMCIVREE. GRAIL (GRAL) faces an FDA panel on Sept. 23. Teledyne (TDY) to buy Varex (VREX) for about $1.1B; Aura (AURA) cut 20% staff.

rttnews.comAug 15

$NXTCMedAI 8/10

RTW Bio's Avere To Merge With NextCure

RTW Biotech Opportunities said its portfolio company Avere Therapeutics will merge with NextCure Inc. in an all-stock deal expected to close by year-end. The combined firm will trade on Nasdaq as Avere Therapeutics under AVRX. Avere plans $820M in private placements, including $5.9M from Avere, to fund AVR-001 Phase 2b psoriasis, Phase 3 psoriasis, and Phase 2b ulcerative colitis.

rttnews.comAug 12

$NXTCMedAI 8/10

Avere Therapeutics to merge with NextCure Inc.

RTW Biotech Opportunities said private portfolio company Avere Therapeutics will go public via an all-stock reverse merger with NextCure Inc., expected by year-end. Avere plans $320 million and $500 million private placements totaling $820 million. The combined company will trade on Nasdaq as Avere Therapeutics, Inc. under ticker AVRX, funding AVR-001 through psoriasis Phase 2b and Phase 3, and ulcerative colitis Phase 2b.

investegate.co.ukAug 12

$NXTCMed

NextCure Reports Q2 Loss As Proposed Avere Merger Reshapes Strategic Direction

NextCure (NXTC) reported Q2 2026 net loss of $14.9M, narrower than $26.8M a year earlier, with lower R&D and G&A expenses. It also recorded $5.1M asset impairments. NextCure said its all-stock merger with Avere Therapeutics is expected to close in H2 2026, with the combined firm trading as AVRX and Avere pursuing about $320M gross private financing.

rttnews.comAug 10